Exhibit 107
Calculation of Filing Fee Tables
Form F-3
(Form Type)
ADC Therapeutics SA
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | Carry Forward Form Type | Carry Forward File Number | Carry Forward Initial Effective Date | Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |
| Newly Registered Securities | ||||||||||||
| Fees to be Paid | Equity | Common Shares | Rule 457(c) | 4,412,840 (1) | $6.95 (2) | $30,669,238 | 0.0000927 | $2,843.04 | ||||
| Fees Previously Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||
| Carry Forward Securities | ||||||||||||
| Carry Forward Securities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||
| Total Offering Amounts | $30,669,238 | $2,843.04 | ||||||||||
| Total Fees Previously Paid | N/A | |||||||||||
| Total Fee Offsets | $2,843.04 | |||||||||||
| Net Fee Due | $0 | |||||||||||
(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, the Registrant is also registering hereunder an indeterminate number of common shares that may be issued in connection with anti-dilution provisions or stock splits, stock dividends or similar transactions.
(2) Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended. The maximum price per share and maximum aggregate offering price are based on the average of the high and low sale prices of the common shares as reported on the New York Stock Exchange on August 30, 2022, which date is within five business days prior to filing this registration statement.
Table 2: Fee Offset Claims and Sources
| Registrant or Filer Name | Form or Filing Type | File Number | Initial Filing Date | Filing Date | Fee Offset Claimed | Security Type Associated with Fee Offset Claimed | Security Title Associated with Fee Offset Claimed | Unsold Securities Associated with Fee Offset Claimed | Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | Fee Paid with Fee Offset Source | |
| Rules 457(b) and 0-11(a)(2) | |||||||||||
| Fee Offset Claims | N/A | N/A | N/A | N/A | |||||||
| Fee Offset Sources | N/A | N/A | N/A | N/A | N/A | ||||||
| Rule 457(p) | |||||||||||
| Fee Offset Claims | ADC Therapeutics SA | F-3 | 333-256686 (1) | June 1, 2021 | $2,843.04 | Equity | Common Shares | 5,558,318 | $13,171.28 | ||
| Fee Offset Sources | ADC Therapeutics SA | F-3 | 333-256686 (1) | June 1, 2021 | $2,843.04 | ||||||
(1) The Registrant has terminated the offering of securities under this registration statement. No securities were sold pursuant to this registration statement.
